European Commission approves Biocon Biologics' Ustekinumab Biosimilar

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the European Commission (EC) granted marketing authorisation in the European Union (EU) for YESINTEK®, a biosimilar of Ustekinumab.

YESINTEK®, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease. Clinical data from the trial program showed that Ustekinumab biosimilar has comparable safety and efficacy to the originator product.

The marketing authorisation approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued on December 14, 2024.

Shares of Biocon Limited was last trading in BSE at Rs. 338.15 as compared to the previous close of Rs. 347.80. The total number of shares traded during the day was 145257 in over 3668 trades.

The stock hit an intraday high of Rs. 352.95 and intraday low of 334.00. The net turnover during the day was Rs. 49249626.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 BioconBiologics EuropeanCommission MarketingAuthorisation EU YESINTEK Biosimilar Ustekinumab